A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of BHV-3500 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs BHV-3500 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Biohaven Pharmaceutical Holding Company
- 22 Oct 2018 Status changed from planning to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
- 22 Oct 2018 According to a Biohaven Pharmaceutical media release, the first participant in this trial has been dosed with BHV-3500.The initiation of dosing follows Biohavens filing of an investigational new drug application (IND) for BHV-3500 in the treatment of migraine and receipt from FDA of authorization to proceed with the clinical investigation of this product candidate.
- 12 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the trial is scheduled to begin in the first half of 2018.